Plain-English translation of NCT07354516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new eye drop medication called QLS-111-FDC to see if it works well for lowering eye pressure in people with open-angle glaucoma or ocular hypertension. The study will compare this new medication to an existing eye drop treatment (latanoprost) over a two-week period. Researchers want to know if the new treatment is safe and effective at reducing the eye pressure that can damage your vision.
Open-angle glaucoma and high eye pressure are serious conditions that can lead to vision loss if not properly treated. This trial exists to find out whether this medication offers a better or equally effective option for patients who need help managing their eye pressure.
If you join this study, you will visit the clinic 5 times over two weeks. At each visit, your eye pressure will be measured and your eyes will be examined. You will be randomly assigned to either the new eye drop medication (QLS-111-FDC) or the comparison medication (latanoprost), and you won't know which one you're receiving. You'll use your assigned eye drops daily at home, and the study team will check how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Qlaris Bio, Inc.
Enrollment target
~64 participants
Started
March 2026
Primary completion
July 2026
Age range
12 Years and older
Last updated on clinicaltrials.gov in July 2026.